After Cantor Fitzgerald and Piper Jaffray gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Difei Yang maintained a Buy rating on Revance Therapeutics today and set a price target of $48. The company’s shares closed yesterday at $24.25, close to its 52-week low of $22.25.
“We also highlight the fact that 150 kDa of RT-002 translates into greater duration compared to 150 kDa of Botox. While a higher dose may improve the duration of Botox, the dose-duration relationship cannot be directly compared to RT-002 due to the unique nature of botulinum toxin products.”
According to TipRanks.com, Yang is a top 100 analyst with an average return of 25.4% and a 55.4% success rate. Yang covers the Healthcare sector, focusing on stocks such as Alder Biopharmaceuticals, Audentes Therapeutics, and Nektar Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $49 average price target, implying a 102.1% upside from current levels. In a report issued on September 14, Cantor Fitzgerald also assigned a Buy rating to the stock with a $50 price target.
The company has a one-year high of $37.45 and a one-year low of $22.25. Currently, Revance Therapeutics has an average volume of 256.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biopharmaceutical company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.